Teva In Transition: Generics, Specialty And 'The Space Between'

In an interview with Scrip's sister publication "The Pink Sheet", President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva's late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.

Teva Pharmaceutical Industries Ltd. is in the midst of making big changes that management believes will position it for sustainable long-term growth. As part of the new strategy, Teva...